Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Patel A, Hoda RS, Hoda SA. Papillary Breast Tumors: Continuing Controversies and Commentary on WHO's 2019 Criteria and Classification. Int J Surg Pathol. 2021:10668969211035843.

Penney KL, Tyekucheva S, Rosenthal J, Fandy HE, Carelli R, Borgstein S, et al. Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. Mol Cancer Res. 2021;19(3):475-484.

Way GP, Greene CS, Carninci P, Carvalho BS, de Hoon M, Finley SD, et al. A field guide to cultivating computational biology. PLoS Biol. 2021;19(10):e3001419.

Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year. bioRxiv. 2021.

Sussman RT, Manning B, Ackerman D, Bigdeli A, Pammer P, Velu PD, et al. Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML. Cancer Genet. 2021;256-257:68-76.

Gao J, Fu L, Lu X, Sukhanova M, Frankfurt O, Mohtashamian A, et al. Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of mutation and genetic complexity. Leuk Lymphoma. 2021:1-4.

Chapel DB, Lee EK, Da Silva AF, Teschan N, Feltmate C, Matulonis UA, et al. Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases. Mod Pathol. 2021;34(3):613-626.

Sun M, Schaap A, Robinson BD, Nanus DM, Tagawa ST. A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. Am J Clin Exp Urol. 2021;9(5):390-396.

Racine-Brzostek SE, Karbaschi M, Gaebler C, Klasse PJ, Yee J, Caskey M, et al. TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. medRxiv. 2021.

Chen C-, Chen B-, Wang Y, Curman P, Beilinson HA, Brecht RM, et al. Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) activity is required for V(D)J recombination. J Exp Med. 2021;218(8).